2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR
  5. CCR5 Isoform
  6. CCR5 Inhibitor

CCR5 Inhibitor

CCR5 Inhibitors (8):

Cat. No. Product Name Effect Purity
  • HY-123902
    Ophiobolin C
    		Inhibitor
    Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells. Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells.
  • HY-P1034
    DAPTA
    		Inhibitor 99.85%
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
  • HY-101713
    Ilacirnon
    		Inhibitor 99.87%
    CCX140 (CCX140-B) is a potent CCR2 antagonist.
  • HY-111069
    Nifeviroc
    		Inhibitor 98.17%
    Nifeviroc is an orally active CCR5 antagonist. Nifeviroc is used for the study of HIV type-1 infection.
  • HY-152132
    CCR5 antagonist 3
    		Inhibitor
    CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC50 of 15.90 nM. CCR5 antagonist 3 shows broad-spectrum anti-HIV-1 activities.
  • HY-111321
    Fuscin
    		Inhibitor
    Fuscin, a fungal metabolite, CCR5 receptor antagonist with anti-HIV effects. Fuscin is a respiration and oxidative phosphorylation inhibitor, and also a mitochondrial SH-dependent transport-linked functions inhibitor.
  • HY-103406
    PNU-177864
    		Inhibitor
    PNU-177864 is a potent, selective, orally active dopamine D3 receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity.
  • HY-162512
    CB-0821
    		Inhibitor
    CB-0821 is a high affinity CCR5 inhibitor with a Ki of 0.04 nM. CB-0821 binds efficiently to the hydrophobic pocket of the CCR5 protein, to inhibit the interactions between viral protein and CCR5, thereby inhibiting viral entry. CB-0821 has the potential for anti-HIV research.